A randomized phase II clinical trial of stereotactic body radiation therapy (SBRT) and systemic pembrolizumab with or without intratumoral avelumab/ipilimumab plus CD1c (BDCA-1)+/CD141 (BDCA-3)+ myeloid dendritic cells in solid tumors
Cancer Immunology, Immunotherapy · 2024
DOI: 10.1007/s00262-024-03751-0 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Cancer Immunology, Immunotherapy, 2024. Verfasst von Manon Vounckx und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Laboratory for Medical and Molecular Oncology (LMMO), Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Bruss…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Radiosurgery, Dendritic Cells, Ipilimumab. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Radiotherapy (RT) synergizes with immune checkpoint blockade (ICB). CD1c(BDCA-1) + /CD141(BDCA-3) + myeloid dendritic cells (myDC) in the tumor microenvironment are indispensable at initiating effector T-cell responses and response to ICB.
Methods
In this phase II clinical trial, anti-PD-1 ICB pretreated oligometastatic patients (tumor agnostic) underwent a leukapheresis followed by isolation of CD1c(BDCA-1) + /CD141(BDCA-3) + myDC. Following hypofractionated stereotactic body RT (3 × 8 Gy), patients were randomized (3:1). Respectively, in arm A (immediate treatment), intratumoral (IT) ipilimumab (10 mg) and avelumab (40 mg) combined with intravenous (IV) pembrolizumab (200 mg) were administered followed by IT injection of myDC; subsequently, IV pembrolizumab and IT ipilimumab/avelumab were continued (q3W). In arm B (contemporary control arm), patients received IV pembrolizumab, with possibility to cross-over at progression. Primary endpoint was 1-year progression-free survival rate (PFS). Secondary endpoints were safety, feasibility, objective response rate, PFS, and overall survival (OS).
Results
Thirteen patients (10 in arm A, eight non-small cell lung cancer, and five melanoma) were enrolled. Two patients crossed over. One-year PFS rate was 10% in arm A and 0% in arm B. Two patients in arm A obtained a partial response, and one patient obtained a stable disease as best response. In arm B, one patient obtained a SD. Median PFS and OS were 21.8 weeks (arm A) versus 24.9 (arm B), and 62.7 versus 57.9 weeks, respectively. An iatrogenic pneumothorax was the only grade 3 treatment-related adverse event.
Conclusion
SBRT and pembrolizumab with or without IT avelumab/ipilimumab and IT myDC in oligometastatic patients are safe and feasible with a clinically meaningful tumor response rate. However, the study failed to reach its primary endpoint. Trial registration number : Clinicaltrials.gov: NCT04571632 (09 AUG 2020). EUDRACT: 2019-003668-32. Date of registration : 17 DEC 2019, amendment 1: 6 MAR 2021, amendment 2: 4 FEB 2022.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Laboratory for Medical and Molecular Oncology (LMMO), Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Laarbeeklaan 101, 1090, Brussels, Belgium. Manon.voun…
- Department of Medical Oncology, Laboratory for Medical and Molecular Oncology (LMMO), Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Laarbeeklaan 101, 1090, Brussels, Belgium.
- Department of Radiology, Universitair Ziekenhuis Brussel (UZ Brussel), Laarbeeklaan 101, 1090, Brussels, Belgium.
- Department of Pathology, Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Laarbeeklaan 101, 1090, Brussels, Belgium.
- Department of Hematology, Stem Cell Laboratory, Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Laarbeeklaan 101, 1090, Brussels, Belgium.
- Department of Radiotherapy, Universitair Ziekenhuis Brussel (UZ Brussel), Laarbeeklaan 101, 1090, Brussels, Belgium.
Zitieren
APA
Vounckx, M., Tijtgat, J., Stevens, L., Dirven, I., Ilsen, B., Vandenbroucke, F., Raeymaeckers, S., Vekens, K., Forsyth, R., Geeraerts, X., Van Riet, I., Schwarze, J. K., Tuyaerts, S., Decoster, L., De Ridder, M., Dufait, I., & Neyns, B. (2024). A randomized phase II clinical trial of stereotactic body radiation therapy (SBRT) and systemic pembrolizumab with or without intratumoral avelumab/ipilimumab plus CD1c (BDCA-1)+/CD141 (BDCA-3)+ myeloid dendritic cells in solid tumors. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-024-03751-0
Vancouver
Vounckx M, Tijtgat J, Stevens L, Dirven I, Ilsen B, Vandenbroucke F, et al. A randomized phase II clinical trial of stereotactic body radiation therapy (SBRT) and systemic pembrolizumab with or without intratumoral avelumab/ipilimumab plus CD1c (BDCA-1)+/CD141 (BDCA-3)+ myeloid dendritic cells in solid tumors. Cancer Immunology, Immunotherapy. 2024. doi:10.1007/s00262-024-03751-0
BibTeX
@article{Vounckx2024,
author = {Vounckx, Manon and Tijtgat, Jens and Stevens, Latoya and Dirven, Iris and Ilsen, Bart and Vandenbroucke, Frederik and Raeymaeckers, Steven and Vekens, Karolien and Forsyth, Ramses and Geeraerts, Xenia and Van Riet, Ivan and Schwarze, Julia Katharina and Tuyaerts, Sandra and Decoster, Lore and De Ridder, Mark and Dufait, Ines and Neyns, Bart},
title = {A randomized phase II clinical trial of stereotactic body radiation therapy (SBRT) and systemic pembrolizumab with or without intratumoral avelumab/ipilimumab plus CD1c (BDCA-1)+/CD141 (BDCA-3)+ myeloid dendritic cells in solid tumors},
journal = {Cancer Immunology, Immunotherapy},
year = {2024},
doi = {10.1007/s00262-024-03751-0}
}
EUVIMED